Piperidine and tetrahydropyridine derivatives
    9.
    发明授权
    Piperidine and tetrahydropyridine derivatives 失效
    哌啶和四氢吡啶衍生物

    公开(公告)号:US5973156A

    公开(公告)日:1999-10-26

    申请号:US68723

    申请日:1998-05-13

    摘要: A class of substituted piperidine and tetrahydropyridine derivatives, linked through the 4-position thereof via an alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, and further substituted at the 1-position by an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl-alkyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.spsb..alpha. receptor subtype whilst processing at least a 10-fold selective affinity for the 5-HT.sub.1D.spsb..alpha. receptor subtype relative to the 5-HT.sub.1D.spsb..beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

    摘要翻译: PCT No.PCT / GB96 / 02795 Sec。 371日期1998年5月13日 102(e)日期1998年5月13日PCT 1996年11月14日PCT PCT。 公开号WO97 / 19073 日期1997年5月29日一类取代的哌啶和四氢吡啶衍生物,其通过其4-位通过亚烷基链连接到稠合的双环杂芳族部分如吲哚基,并且在1位被进一步被任选取代的烷基,烯基, 炔基,环烷基 - 烷基,芳基 - 烷基或杂芳基 - 烷基部分是5-HT1样受体的选择性激动剂,其是人类5-HT1Dα受体亚型的有效激动剂,同时处理至少10倍的选择性亲和力 5-HT1Dα受体亚型相对于5-HT1Dβ亚型; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。